Sunday 18 October 2026
Export RLMD’s income statement to Excel — free account
Relmada Therapeutics, Inc.
RLMD Healthcare Biotechnology
In the quarter to June 2026, EPS grew 63.3% and free cash flow fell 50.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.10
0.10
−3.13%
Follow RLMD
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 2.44 | 2.52 | 2.44 | 4.60 | 23.25 | 16.34 | 1.81 | 2.00 | 0.34 | 0.24 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | 16.40 | 5.60 | 7.76 | 48.00 | 54.00 | 40.00 | 38.68 | 4.85 | 7.22 | 5.12 | |||||
| People | |||||||||||||||
| People | Employees | 6 | 3 | 3 | 4 | 14 | 10 | 14 | 20 | 17 | 17 | ||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | |||||
| EBT | (3) | (6) | (9) | (15) | (59) | (126) | (157) | (99) | (80) | (57) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | (3) | (6) | (9) | (15) | (59) | (126) | (157) | (99) | (80) | (57) | |||||
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | — | — | — | — | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (1.04) | (2.08) | (2.84) | (1.62) | (3.81) | (7.16) | (5.30) | (3.28) | (2.65) | (1.45) | |||||
| Cash flow | (4.53) | (2.14) | (1.91) | (1.31) | (1.78) | (5.23) | (3.50) | (1.72) | (1.72) | (1.16) | |||||
| Capex | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | (4.53) | (2.14) | (1.91) | (1.31) | (1.78) | (5.23) | (3.50) | (1.72) | (1.72) | (1.16) | |||||
| Book value | 2.43 | 0.48 | (1.76) | 12.52 | 6.77 | 11.87 | 4.74 | 2.84 | 1.18 | 2.19 | |||||
| Shares, m | 3 | 3 | 3 | 9 | 16 | 18 | 30 | 30 | 30 | 39 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (13) | (6) | (6) | (12) | (28) | (92) | (104) | (52) | (52) | (46) | ||||
| Capex | (1) | 0 | 0 | — | — | — | — | — | — | — | |||||
| Free cash flow | (13) | (6) | (6) | (12) | (28) | (92) | (104) | (52) | (52) | (46) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 6 | 1 | (3) | 115 | 105 | 208 | 140 | 85 | 36 | 88 | ||||
| Total debt | 0 | 0 | 3 | 0 | — | — | — | — | — | — | |||||
| Net debt | (9) | (2) | (2) | (116) | (117) | (212) | (148) | (96) | (45) | (93) | |||||
| Shareholders’ equity | 7 | 1 | (6) | 116 | 106 | 208 | 140 | 85 | 36 | 87 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (29.04) | (221.60) | (293.98) | (23.56) | (50.53) | (73.64) | (83.48) | (78.89) | (111.57) | (82.08) | ||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | (42.24) | (430.49) | 162.54 | (24.34) | (53.74) | (80.14) | (90.07) | (87.51) | (132.33) | (94.05) | |||||
Negative figures in brackets.
Charts ten years each
Relmada Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| AVIR Atea Pharmaceuticals, Inc. | $363.3M | — (loss-making) | — (loss-making) | +295.16% (above 0%: growing) | n/m | +85.53% (above 0%: growing) | 0.00% | 0.00% | Compare |
| FENC Adherex Technologies Inc. | $362.9M | — (loss-making) | 31.4× | +85.18% (above 0%: growing) | n/m | +101.36% (above 0%: growing) | 95.97% | 9.72% | Compare |
| TTRX Turn Therapeutics Inc. | $345.3M | — (loss-making) | — | — | n/m | −74.76% (below 0%: shrinking) | — | 0.00% | Compare |
| OBIO Orchestra BioMed Holdings, Inc. | $345.0M | — (loss-making) | — (loss-making) | −89.47% (below 0%: shrinking) | n/m | −25.87% (below 0%: shrinking) | 71.59% | (25,404.55%) | Compare |
| CCCC C4 Therapeutics, Inc. | $342.0M | — (loss-making) | — (loss-making) | +2.75% (above 0%: growing) | n/m | +86.84% (above 0%: growing) | 100.00% | (397.88%) | Compare |
| RLMD Relmada Therapeutics, Inc. | $341.3M | — (loss-making) | — | — | n/m | −50.06% (below 0%: shrinking) | 0.00% | 0.00% | |
| IRD Opus Genetics, Inc. | $336.9M | — (loss-making) | — (loss-making) | −73.80% (below 0%: shrinking) | n/m | −16.37% (below 0%: shrinking) | 100.00% | (2,182.78%) | Compare |
| ENTA Enanta Pharmaceuticals, Inc. | $334.1M | — (loss-making) | — (loss-making) | −21.60% (below 0%: shrinking) | n/m | −157.51% (below 0%: shrinking) | 100.00% | (120.04%) | Compare |
| CYPH Cypherpunk Technologies Inc. | $325.5M | 4.4× | — (loss-making) | 0.00% | n/m | +15.53% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $343.5M | — | — | 0.00% | — | −0.42% | 95.97% | (60.02%) |
Relmada Therapeutics, Inc. (RLMD) key facts
- Relmada Therapeutics, Inc. (RLMD) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, RLMD traded at $3.10, a market capitalization of $341.3 million.
- Return on equity was −94.1% and debt-to-equity 0.00.